Lv1
40 积分 2024-09-04 加入
Nanobodies for inflammatory bowel disease: Miniaturizing solutions
1个月前
已完结
Understanding the therapeutic toolkit for inflammatory bowel disease
1个月前
已完结
First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers
1个月前
已完结
Interleukin‐25 recognition by its unique receptor IL‐17Rb via two discrete linear and cyclic epitopes
1个月前
已完结
The IL-33/ST2 pathway: therapeutic target and novel biomarker
2个月前
已完结
The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus
2个月前
已完结
The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment
2个月前
已完结
Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients
2个月前
已完结
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
5个月前
已完结
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
5个月前
已完结
皖公网安备34019202002308
